CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00643994
Recruitment Status : Active, not recruiting
First Posted : March 26, 2008
Last Update Posted : July 18, 2016
Information provided by (Responsible Party):
Accuray Incorporated

Brief Summary:
The purpose of this study is to determine the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer Prostatic Cancer Prostate Neoplasms Prostatic Neoplasms Cancer of the Prostate Radiation: CyberKnife Stereotactic Radiosurgery Phase 2

Detailed Description:
The CyberKnife Robotic Radiosurgery System is a unique radiosurgical system capable of treating tumors anywhere in the body noninvasively and with sub-millimeter accuracy. The CyberKnife System delivers radiation using a precise targeting methodology allowing a focal treatment margin around the target, thus limiting the volume of adjacent tissue receiving high doses radiation. This in turn allows the delivery of high doses of radiation to the prostate over a short series of treatments.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 298 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Homogenous Dose Distribution
Study Start Date : December 2007
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : January 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: CyberKnife Stereotactic Radiosurgery Radiation: CyberKnife Stereotactic Radiosurgery
36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
Other Name: CyberKnife

Primary Outcome Measures :
  1. To estimate, in both low-risk and intermediate-risk cohorts, the rates of acute and late grade 3-5 gastrointestinal and genitourinary toxicities observed following CyberKnife treatment for prostate cancer. [ Time Frame: 10 years ]
  2. To determine the rate of biochemical Disease-Free Survival (bDFS), using the Phoenix and ASTRO definitions, following CyberKnife treatment. [ Time Frame: 10 years ]

Secondary Outcome Measures :
  1. To determine the rates of local failure, distant failure, disease-free survival, disease-specific survival, overall survival and quality of life following CyberKnife treatment in prostate cancer patients. [ Time Frame: 10 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient must be at least 18 years of age
  • Histologically proven prostate adenocarcinoma
  • Patients belonging in one of the following risk groups:

Low: CS T1b-T2a and Gleason 2-6 and PSA ≤ 10, or Intermediate: CS T2b and Gleason 2-6 and PSA ≤ 10 or CS T1b-T2b, and Gleason 2-6 and PSA ≤ 20 ng/ml or Gleason 7 and PSA ≤ 10 ng/ml

  • Prostate volume: ≤ 100 cc
  • ECOG performance status 0-1

Exclusion Criteria:

  • Prior prostatectomy or cryotherapy of the prostate
  • Prior radiotherapy to the prostate or lower pelvis
  • Implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion
  • Chemotherapy for a malignancy in the last 5 years
  • History of an invasive malignancy (other than this prostate cancer, or basal or squamous skin cancers) in the last 5 years.
  • Hormone ablation for two months prior to enrollment, or during treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00643994

  Hide Study Locations
United States, Arizona
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States, 85013
United States, California
Scripps Cancer Center - CyberKnife of Southern California at Vista
La Jolla, California, United States, 92037
The CyberKnife at Newport Diagnostic Center
Newport Beach, California, United States, 92660
United States, District of Columbia
Georgetown University
Washington, District of Columbia, United States, 20057
United States, Florida
Coastal CyberKnife and Radiation Oncology
Fort Pierce, Florida, United States, 34982
Jupiter Medical Center & CyberKnife Center of Palm Beach
Jupiter, Florida, United States, 33458
United States, Illinois
Northwest Community Hospital
Arlington Heights, Illinois, United States, 60005
Community Cancer Center
Normal, Illinois, United States, 61761
United States, Kentucky
Central Baptist Hospital
Lexington, Kentucky, United States, 40503
United States, Maryland
Sinai Hospital of Baltimore
Baltimore, Maryland, United States, 21215
Franklin Square Hospital Center
Baltimore, Maryland, United States, 21237
United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
United States, Michigan
St. Joseph Mercy Hospital
Ann Arbor, Michigan, United States, 48106
United States, Missouri
Lake Saint Louis Oncology
Saint Louis, Missouri, United States, 63367
Saint Louis University
St. Louis, Missouri, United States, 63367
United States, Nevada
St. Mary's Regional Medical Center
Reno, Nevada, United States, 89503
United States, New Jersey
Capital Health
Trenton, New Jersey, United States, 08618
United States, New York
Hematology Oncology Associates of Central New York
Syracuse, New York, United States, 15057
United States, Virginia
Virginia Hospital Center
Arlington, Virginia, United States, 22205
United States, Washington
Swedish Cancer Center
Seattle, Washington, United States, 98122
Southwest Washington Medical Center
Vancouver, Washington, United States, 98664
Southwest Washington Regional Cancer Center
Vancouver, Washington, United States, 98664
United States, Wisconsin
ThedaCare Appleton Medical Center
Appleton, Wisconsin, United States, 54911
Sponsors and Collaborators
Accuray Incorporated
Study Chair: Robert Meier, MD Swedish Cancer Center
Study Chair: Irving Kaplan, MD Beth Israel Deaconess Medical Center
Study Chair: Martin Sanda, MD Beth Israel Deaconess Medical Center

Additional Information:
Responsible Party: Accuray Incorporated Identifier: NCT00643994     History of Changes
Other Study ID Numbers: ACCP001.3
First Posted: March 26, 2008    Key Record Dates
Last Update Posted: July 18, 2016
Last Verified: July 2016

Keywords provided by Accuray Incorporated:
Prostate Cancer
Stereotactic Radiosurgery
Prostate Tumor
Prostate Surgery

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases